Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Documenti analoghi

• Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
  di: Mathisen, Michael S., et al.
  Pubblicazione: (2011)
• Outcomes of Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
  di: Maiti, Abhishek, et al.
  Pubblicazione: (2020)
• New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
  di: FULLMER, AMBER, et al.
  Pubblicazione: (2011)
• Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
  di: Quintás-Cardama, Alfonso, et al.
  Pubblicazione: (2009)
• Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
  di: Jabbour, Elias, et al.
  Pubblicazione: (2008)